Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/34888

Adverse Events Leading to Discontinuation of Phototherapy: An Observational Study

Título :
Adverse Events Leading to Discontinuation of Phototherapy: An Observational Study
Autor :
Belinchón, Isabel  
Sánchez-Pujol, María J.
Docampo, Alejandro
Cuesta, Laura
Schneller-Pavelescu, Luca  
Ramos Rincón, José Manuel
Editor :
Medical Journals Sweden
Departamento:
Departamentos de la UMH::Medicina Clínica
Fecha de publicación:
2020
URI :
https://hdl.handle.net/11000/34888
Resumen :
The aim of this prospective study in a phototherapy unit was to describe adverse events (AEs) associated with discontinuation of phototherapy in a clinical setting. A total of 872 included patients received 1,256 courses of phototherapy treatment: 76.9% narrow-band UVB (NBUVB); 9.6% systemic psoralen plus UVA (PUVA); 11.4% topical PUVA; and 2.1% UVA. Approximately a fifth of the treatments (n = 240, 19.1%) were associated with AEs, the most frequent of which was erythema (8.8%). Systemic PUVA had the highest rate of AEs (32.5%). Mycosis fungoides was the dermatosis with the highest rate of AE (36.9%). A total of 216 (17.2%) patients stopped treatment: 23.6% because of AEs (4.1% of all treatments). Treatment suspension due to AEs was associated with PUVA, both topical and systemic (p < 0.001), and diagnoses of mycosis fungoides (p <0.001), palmoplantar psoriasis (p = 0.002), hand eczema (p = 0.002) and pityriasis lichenoides (p = 0.01). In conclusion, one in every 5 patients receiving phototherapy had an AE, but few stopped treatment for this reason.
Palabras clave/Materias:
phototherapy
adverse events
discontinuation
narrow-band UVB
psoralen plus UVA
Tipo de documento :
info:eu-repo/semantics/article
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI :
10.2340/00015555-3453
Aparece en las colecciones:
Artículos Medicina Clínica



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.